Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- A New Industry Could Be Created in the Field of Pre-Symptomatic Medical Intervention: Kyoto Univ. Prof. Kawakami
January 16, 2012
- Specialists Debate Pro, Cons of Early Pharm. Intervention in Dementia
January 16, 2012
- MD Studies Could Increase Development Success Rate to 30%: Prof. Sugiyama
December 20, 2011
- Kyushu University Professor Egashira Says Suppression of Vascular Inflammation Can Be Target for Development
November 30, 2011
- JDA Requests Additional Indication of Pustular Psoriasis for Humira
November 22, 2011
- JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
- JUA Negative about OTC Switching of Propiverine Hydrochloride
November 17, 2011
- PSJ Preparing for Exchange of Views with JAMS on Switch-OTC Drug Candidates
November 15, 2011
- Teriparatide “Strongly Recommended” for Non-vertebral Fracture: JOS Draft GLs
November 7, 2011
- “No Major Ethnic Differences” in Pharmacokinetics of 3 Drugs Reported
November 1, 2011
- JSGM Calls for Elimination of GE Drug Refusal Option in Prescriptions
October 28, 2011
- JSGM Calls For Elimination of GE Drug Refusal Option in Prescriptions
October 27, 2011
- “No Major Differences” Between 4 AD Treatments; More Evidence Needed: Prof. Hanyu
October 20, 2011
- Kyowa Kirin’s KW-0761 Shows Promise for ATL: Prof. Tsukasaki of Nagasaki Univ.
October 20, 2011
- Positive Results for Avastin in Japanese PII Trial in Recurrent GBM: JNS
October 13, 2011
- Nexium Significantly Reduces Incidence of Acid Reflux Compared to Omepral: Study Report
October 10, 2011
- Prof. Uchiyama Stresses Need for Caution with Prazaxa Even at Low Dose
October 10, 2011
- JGS Opposes OTC Switch for 8 Ethical Drugs on Ground of Patients’ High Ages
October 7, 2011
- HRT is Cost Efficient Treatment: JSMWH
October 6, 2011
- Humira Top Choice Among Biopharmaceuticals for Psoriasis Treatment: Prof. Nakagawa
October 6, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…